

## 4 510(k) Summary of Safety and Effectiveness

<i>Date Summary Prepared</i>	March 2, 2011
<i>Manufacturer/Distributor /Sponsor</i>	Arthrex, Inc. 1370 Creekside Boulevard Naples, FL 34108-1945 USA
<i>510(k) Contact</i>	Courtney Smith Regulatory Affairs Project Manager Arthrex, Inc. 1370 Creekside Boulevard Naples, FL 34108-1945 USA Telephone: 239/643.5553, ext. 1720 Fax: 239/598.5508 Email: <a href="mailto:csmith@arthrex.com">csmith@arthrex.com</a>
<i>Trade Name</i>	<b>Arthrex BioComposite SutureTak</b>
<i>Common Name</i>	Suture Anchor
<i>Product Code - Classification Name</i>	<b>HWC</b> – Screw, fixation, bone <b>MAI</b> – Fastener, fixation, biodegradable, soft tissue
<i>Predicate Devices</i>	K091844: Arthrex BioComposite SutureTak Anchors
<i>Device Description and Intended Use</i>	<p>The <b>Arthrex BioComposite SutureTak</b> is a 2.0mm biocomposite suture anchor with a molded-in suture eyelet. The anchor is loaded on a driver and pre-loaded polyester suture.</p> <p>The <b>Arthrex BioComposite SutureTak</b> family is intended to be used for suture or tissue fixation in the foot, ankle, knee, hand, wrist, shoulder, and elbow. Please see indications for use form for specific indications.</p>
<i>Substantial Equivalence Summary</i>	<p>The <b>Arthrex BioComposite SutureTak</b> is substantially equivalent to the Arthrex BioComposite SutureTak Anchors (K091844), in which the basic features, materials and intended uses are the same. Any differences between the <b>BioComposite SutureTak</b> and the predicate are considered minor and do not raise questions concerning safety and effectiveness.</p> <p>The submitted mechanical testing data demonstrated that the ultimate load strength of the proposed devices after 16 weeks of degradation meets or exceeds the minimum acceptance criteria. Based on the indication for use, technological characteristics, and the comparison to the predicate devices, Arthrex, Inc. has determined that the <b>Arthrex BioComposite SutureTak</b> is substantially equivalent to currently marketed predicate devices.</p>



Food and Drug Administration  
10903 New Hampshire Avenue  
Document Control Room –WO66-G609  
Silver Spring, MD 20993-0002

Arthrex, Inc.  
% Courtney Smith  
Regulatory Affairs Project Manager  
1370 Creekside Boulevard  
Naples, Florida 34108-1945

MAR 31 2011

Re: K110660

Trade/Device Name: Arthrex BioComposite SutureTak  
Regulation Number: 21 CFR 888.3030  
Regulation Name: Single/multiple component metallic bone fixation appliance  
and accessories

Regulatory Class: Class II  
Product Code: MAI, HWC  
Dated: March 02, 2011  
Received: March 09, 2011

Dear Courtney Smith:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you; however, that device labeling must be truthful and not misleading.


If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to <http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm> for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>.

Sincerely yours,



Mark N. Melkerson  
Director  
Division of Surgical, Orthopedic  
And Restorative Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure

### 3 Indications for Use Form

#### Indications for Use

510(k) Number: K110660 (1/1)

Device Name: Arthrex BioComposite SutureTak

**Indications For Use:**

The *Arthrex BioComposite SutureTak* is intended to be used for suture or tissue fixation in the foot, ankle, knee, hand, wrist, elbow, and shoulder. Specific indications are listed below and are size appropriate per patient needs:

- Elbow:** Biceps Tendon Reattachment, Ulnar or Radial Collateral Ligament Reconstruction.
- Shoulder:** Rotator Cuff Repairs; Bankart Repair, SLAP Lesion Repair, Biceps Tenodesis, Acromio-Clavicular Separation Repair, Deltoid Repair, Capsular Shift or Capsulolabral Reconstruction.
- Hand/Wrist:** Scapholunate Ligament Reconstruction, Carpal Ligament Reconstruction, Repair/Reconstruction of Collateral Ligaments, Repair of Flexor and Extensor Tendons at the PIP, DIP and MCP joints for all digits, Digital Tendon Transfers.
- Foot/Ankle:** Lateral Stabilization, Medial Stabilization, Achilles Tendon Repair, Metatarsal Ligament Repair, Hallux Valgus Reconstruction, Digital Tendon Transfers, Mid-foot reconstruction.
- Knee:** Medial Collateral Ligament Repair, Lateral Collateral Ligament Repair, Patellar Tendon Repair, Posterior Oblique Ligament Repair, Iliotibial Band Tenodesis.

Prescription Use  AND/OR Over-The-Counter Use

(Per 21 CFR 801 Subpart D)

(21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

PAGE 1 of 1

  
(Division Sign-Off)  
Division of Surgical, Orthopedic,  
and Restorative Devices

510(k) Number K110660